Intellia Therapeutics (NTLA) Depreciation & Amortization (CF) (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 11.85% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 million (down 7.6% YoY) and the FY2025 annual result came in at $9.8 million, down 4.85% from the prior year.
• Depreciation & Amortization (CF) slipped to $2.2 million in Q1 2026 per NTLA's latest filing, from $2.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.6 million in Q2 2024 and bottomed at $1.8 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $2.4 million (2025), against an average of $2.3 million.
• The widest annual swing landed in 2024, when Depreciation & Amortization (CF) climbed 21.95%; it then dropped 11.85% in 2026.
• Tracing NTLA's Depreciation & Amortization (CF) over 5 years: stood at $2.1 million in 2022, then grew by 19.77% to $2.5 million in 2023, then gained by 5.43% to $2.6 million in 2024, then dropped by 7.19% to $2.4 million in 2025, then retreated by 8.74% to $2.2 million in 2026.
• Per Business Quant, the three latest NTLA Depreciation & Amortization (CF) figures stand at $2.2 million (Q1 2026), $2.4 million (Q4 2025), and $2.4 million (Q3 2025).

Peer Comparison